GlassScriptPhysician profile
Alexandra Gamret
NPI 1912526039
$5,469.37
in general payments reported to CMS, 2019-2025
20 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $1,553 · 2023: $1,582 · 2024: $1,797 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $951.95 | 2023-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $781.08 | 2023-2024 | Sotyktu |
| Abbvie INC. | $540.85 | 2021-2025 | |
| Galderma Laboratories, L.P. | $540.26 | 2022-2025 | Aklief, Nemluvio |
| Allergan, INC. | $443.87 | 2022 | |
| Genzyme Corporation | $431.68 | 2023-2024 | |
| Dermavant Sciences, INC. | $424.06 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $272.36 | 2021-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $199.03 | 2023-2025 | Zoryve |
| Pfizer INC. | $190.02 | 2022-2023 | |
| Incyte Corporation | $154.54 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $148.34 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $101.08 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.61 | 2022-2023 | Targretin, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.38 | 2022-2023 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $46.91 | 2023 | Valchlor |
| Ucb, INC. | $31.16 | 2022 | |
| Biofrontera INC. | $19.17 | 2025 | Ameluz |
| Almirall LLC | $17.79 | 2025 | Klisyri |
| Mimedx Group, INC. | $17.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Gamret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.